A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C

By C. Wai, J. Greenson, R. Fontana, John D. Kalbfleisch, Jorge Marrero, H. Conjeevaram, A. Lok. Hepatology, 2003

4,446 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/be66dae868a398c10780dd310cee41cfc13e5826

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis (2011, methodology): “At the lower threshold of 0.5 recommended by Wai et al., the summary sensitivities and specificities were 74% (95% confidence interval [CI], 73%-76”
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016, neutral): “87 66 91 73 87 - Developed in hepatitis C [46]; predicts liverrelated events [37, 40] McPherson 2010 [47] AST/ALT ratio AST, ALT 145 >0.”
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. (2005, background): “Many published studies have also developed panels of serum markers applicable to fibrosis prediction in hepatitis C–infected patients (13, 15, 16, 19, 26, 27); however, our study has several unique features.”
Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis (2017, methodology): “Dozens of noninvasive models composed of blood biochemical biomarkers have been proposed to detect LF, including aspartate aminotransferase to platelets ratio index (APRI)((5)) and fibrosis-4 index (FIB-4).”
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases (2019, background): “Among 14 serum-based biomarker panels for hepatic fibrosis, the FibroTest,(247-249) the serum AST/platelet ratio index (APRI),(250) the Fibrosis-4 index (FIB-4),(251,252) and the enhanced liver fibrosis test(253,254) have emerged as the better candidates in AIH.”
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD (2007, neutral): “5 19 (14-25) 98 (97-100) 64 (53-75) 97 (95-98) 10 33 (26-39) 97 (95-99) 78 (68-87) 94 (91-96) 15 42 (35-49) 96 (93-98) 84 (76-93) 91 (88-94) 20 49 (42-56) 94 (91-97) 88 (80-95) 88 (85-91) 25 55 (47-62) 93 (90-96) 90 (83-97) 86 (82-89) 30 59 (52-66) 92 (88-95) 91 (85-98) 83 (80-87) 35 63 (56-70) 90 (”
Evaluation of Liver Fibrosis: A Concise Review (2004, methodology): “A further simple index based upon the AST and platelet count has recently been published by Wai and colleagues and is referred to as the AST to platelet ratio index (APRI)”